# **Hydroxyprogesterone caproate**

## Goal(s):

• To ensure appropriate drug use and limit to patient populations in which hydroxyprogesterone caproate injection has been shown to be effective and safe.

#### **Length of Authorization:**

• 20 weeks to 6 months (criteria-specific)

## **Requires PA:**

• Hydroxyprogesterone caproate injection(physician administered and pharmacy claims)

### **Covered Alternatives:**

- Current PMPDP preferred drug list per OAR 410-121-0030 at www.orpdl.org
- Searchable site for Oregon FFS Drug Class listed at www.orpdl.org/drugs/

Approval Criteria				
1.	What diagnosis is being treated?	Record ICD10 code		
2.	Is the diagnosis funded by OHP?	Yes: Go to #3	No: Pass to RPh. Deny; not funded by the OHP	
3.	Is the drug formulation to be used for an FDA-approved indication?  Message: Only Makena and its generics are approved for prevention of preterm birth	<b>Yes:</b> Go to #4	No: Pass to RPh. Deny; medical appropriateness	
4.	Is the request for a non-preferred product and will the prescriber consider a change to a preferred product?  Message: Preferred products are evidence-based and reviewed for comparative effectiveness and safety by the P&T Committee.	Yes: Inform prescriber of preferred alternatives in class.	<b>No</b> : Go to #5	
5.	Is the request for Delalutin® or its generic products?	Yes: Approve for 6 month	<b>No:</b> Go to #6	
6.	Is the request for Makena or its generics and is the patient between 16 weeks and 36 weeks 6 days gestation with a singleton pregnancy?	Yes: Go to #7	No: Pass to RPh. Deny; medical appropriateness	

Approval Criteria				
7.	Has the patient had a prior history of preterm delivery before 37 weeks gestation (spontaneous preterm singleton birth)?	<b>Yes:</b> Go to #8	<b>No:</b> Pass to RPh. Deny; medical appropriateness	
8.	Is treatment being initiated at 16 weeks, 0 days and to 20 weeks, 6 days of gestation?	Yes: Approve through week 37 of gestation or delivery, whichever occurs first (no more than 20 doses).	<b>No:</b> Pass to RPh. Deny; medical appropriateness	

P&T/DUR Review: Implementation: 3/19 (SS); 1/17 (SS); 5/13 5/1/19; 4/1/17, 1/1/14